TT-702 in Patients With Advanced Solid Tumours.

Required: MLH1 loss of expression

loss of MLH1, MSH2, MSH6, and/or PMS2 expression is detected

Required: MSH2 loss of expression

loss of MLH1, MSH2, MSH6, and/or PMS2 expression is detected

Required: MSH6 loss of expression

loss of MLH1, MSH2, MSH6, and/or PMS2 expression is detected

Required: PMS2 loss of expression

loss of MLH1, MSH2, MSH6, and/or PMS2 expression is detected

Required: HER2 (ERBB2) negative (IHC 0 or 1 or negative FISH) (IHC 0 or 1 or negative FISH)

Human epidermal growth factor receptor 2 negativity (negative immunohistochemistry [IHC] staining [score 0 or 1] or negative fluorescence in situ hybridisation)

Required: ESR1 negative (<1% positive staining cells) (<1% positive staining cells)

ER and progesterone receptor negativity (<1% positive staining cells in the invasive tumour)

Required: PR (PGR) negative (<1% positive staining cells) (<1% positive staining cells)

ER and progesterone receptor negativity (<1% positive staining cells in the invasive tumour)

Must have received: next generation AR antagonist (enzalutamide, apalutamide, darolutamide, abiraterone) — mCRPC

mCRPC previously treated with a next generation AR antagonist (including enzalutamide, apalutamide or darolutamide) or abiraterone

Must have received: anti-PD-1 therapy — MMR/MSI defective tumours

Prior treatment with an anti-PD-1 or anti-PD-L1 agent, either as monotherapy or in combination with other agent(s). This should be the preceding treatment prior to trial entry. Patients must have progressed on an anti-PD-1/anti-PD-L1 agent.

Must have received: anti-PD-1 therapy — TNBC

Patients who have received prior anti-PD-1/anti-PD-L1 agent must have experienced Investigator-assessed initial clinical benefit from the most recent anti-PD-1/anti-PD-L1 treatment (either as monotherapy or in combination with other compounds) for at least 10 weeks, followed by subsequent progression.

Cannot have received: radiotherapy

Exception: single fractions for palliative reasons

Radiotherapy (except single fractions for palliative reasons)...during the previous four weeks

Cannot have received: endocrine therapy

endocrine therapy during the previous four weeks

Cannot have received: immunotherapy

immunotherapy and chemotherapy during the previous four weeks (previous six weeks for nitrosoureas, Mitomycin-C)

Cannot have received: chemotherapy

immunotherapy and chemotherapy during the previous four weeks (previous six weeks for nitrosoureas, Mitomycin-C)

Cannot have received: nitrosoureas

previous six weeks for nitrosoureas

Cannot have received: Mitomycin-C (Mitomycin-C)

previous six weeks for...Mitomycin-C

Cannot have received: bone marrow transplant

Prior bone marrow transplant